To report clinical manifestations, laboratory findings and the outcome of treatment in kidney transplant recipients who had CMV infection in our center. This study was performed retrospectively on the records of the kidney transplant recipients of our center who have followed up regularly from 2001 to 2006; in some patients the complementally information were gathered through telephone call and physical examination in the clinic. The CMV infection diagnosis was also made by detecting PP.65 Antigen in cells per 50,000 leukocytes of peripheral blood. Of the 200 kidney transplant recipients, 66 were infected by CMV including 42 men and 24 women. The patients’ age ranged from 14 to 67 years, with the mean of 40±13 year. Seventy nine percent of patients were infected during the 1st six-month following the transplantation. All except 22 patients (33%) had constitutional complaints. Fever was present in 65% patients, abdominal pain in 21%, diarrhea in 20% and vomiting in 15%. Likewise, pulmonary complaints including cough and dyspnea were reported by 32% and 23%, respectively. However, 20% of patients were completely asymptomatic. Hematologic lab data showed 64% anemia, 47% thrombocytopenia and 21% leukopenia. Seventy eight percent of patients had creatinin ≤2 before infection but it was ≤2 in just 26% when CMV was diagnosed and in 60% after treatment. Antiviral therapy was done with intravenous gancyclovir in 80% of patients and gancyclovir plus acyclovir in 20%. Corticosteroid pulsetherapy was also done in 78% of patients. No statistically significant correlation was found between CMV antigen load and severity of clinical manifestations or the time of response to treatment and also the recurrence prognosis. In our series 1 patient died, 28 patients (42%) treated but experienced CMV recurrence and 37 (56%) showed no recurrence. CMV infection should be considered in any renal transplant recipient who have rise in creatinin even if s/he is symptom free. In spite of the results of other studies, we found no prognostic value for the viral antigen load.